NASDAQ:BIOS - BioScrip Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $2.90 -0.02 (-0.68 %) (As of 07/22/2018 08:46 AM ET)Previous Close$2.90Today's Range$2.84 - $2.9652-Week Range$1.80 - $3.39Volume311,427 shsAverage Volume866,621 shsMarket Capitalization$371.06 millionP/E RatioN/ADividend YieldN/ABeta0.17 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioScrip, Inc. provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. It also offers home nursing products and services to patients suffering from chronic and acute medical conditions. The company offers its services at patient's homes, outpatient clinics, nursing facilities, physician's offices, and ambulatory infusion centers. It markets and sells its products and services through sales and marketing representatives, and payor relationships. The company was founded in 1993 and is based in Denver, Colorado. Receive BIOS News and Ratings via Email Sign-up to receive the latest news and ratings for BIOS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Home health care services Sub-IndustryHealth Care Services SectorMedical SymbolNASDAQ:BIOS CUSIP09069N10 Webwww.bioscrip.com Phone720-697-5200 Debt Debt-to-Equity Ratio-4.79 Current Ratio1.70 Quick Ratio1.30 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$817.19 million Price / Sales0.45 Cash FlowN/A Price / CashN/A Book Value($0.66) per share Price / Book-4.39 Profitability EPS (Most Recent Fiscal Year)($0.44) Net Income$-64,190,000.00 Net Margins-9.23% Return on EquityN/A Return on Assets-8.77% Miscellaneous Employees2,154 Outstanding Shares127,950,000Market Cap$371.06 BioScrip (NASDAQ:BIOS) Frequently Asked Questions What is BioScrip's stock symbol? BioScrip trades on the NASDAQ under the ticker symbol "BIOS." How were BioScrip's earnings last quarter? BioScrip Inc (NASDAQ:BIOS) announced its quarterly earnings data on Thursday, May, 10th. The company reported ($0.12) EPS for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.01. The business earned $168.60 million during the quarter, compared to analysts' expectations of $164.72 million. The business's revenue for the quarter was down 22.6% on a year-over-year basis. During the same period in the previous year, the business earned ($0.18) earnings per share. View BioScrip's Earnings History. When is BioScrip's next earnings date? BioScrip is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for BioScrip. What price target have analysts set for BIOS? 3 analysts have issued 1-year price targets for BioScrip's stock. Their forecasts range from $3.25 to $4.00. On average, they expect BioScrip's share price to reach $3.5833 in the next twelve months. This suggests a possible upside of 23.6% from the stock's current price. View Analyst Ratings for BioScrip. What is the consensus analysts' recommendation for BioScrip? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioScrip in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of BioScrip's key competitors? Some companies that are related to BioScrip include Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), Addus Homecare (ADUS), Civitas Solutions (CIVI) and New York Health Care (BBAL). Who are BioScrip's key executives? BioScrip's management team includes the folowing people: Mr. Daniel E. Greenleaf, CEO, Pres & Director (Age 53)Mr. Stephen M. Deitsch, Sr. VP, CFO & Treasurer (Age 46)Ms. Harriet Booker, Sr. VP & COO (Age 51)Mr. Alex Schott, Sr. VP of Strategic Operations & Interim Chief Accounting Officer (Age 48)Ms. Jody Kepler, Sr. VP, Chief Compliance Officer & Privacy Officer (Age 48) Has BioScrip been receiving favorable news coverage? Press coverage about BIOS stock has trended somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioScrip earned a coverage optimism score of 0.01 on Accern's scale. They also assigned news headlines about the company an impact score of 45.92 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term. Who are BioScrip's major shareholders? BioScrip's stock is owned by a number of of retail and institutional investors. Top institutional investors include Mesirow Financial Investment Management Inc. (0.09%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, Jeffrey M Kreger, Michael G Bronfein, R Carter Pate and Stephen Deitsch. View Institutional Ownership Trends for BioScrip. Which institutional investors are buying BioScrip stock? BIOS stock was purchased by a variety of institutional investors in the last quarter, including Mesirow Financial Investment Management Inc.. Company insiders that have bought BioScrip stock in the last two years include Daniel E Greenleaf, Jeffrey M Kreger, R Carter Pate and Stephen Deitsch. View Insider Buying and Selling for BioScrip. How do I buy shares of BioScrip? Shares of BIOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BioScrip's stock price today? One share of BIOS stock can currently be purchased for approximately $2.90. How big of a company is BioScrip? BioScrip has a market capitalization of $371.06 million and generates $817.19 million in revenue each year. The company earns $-64,190,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. BioScrip employs 2,154 workers across the globe. How can I contact BioScrip? BioScrip's mailing address is 1600 BROADWAY SUITE 700, DENVER CO, 80202. The company can be reached via phone at 720-697-5200 or via email at [email protected] MarketBeat Community Rating for BioScrip (NASDAQ BIOS)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 222 (Vote Outperform)Underperform Votes: 150 (Vote Underperform)Total Votes: 372MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe BIOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: What does earnings per share mean?